Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



King's College London - Health: More than a medical matter





Single HIV gene therapy may replace lifetime of drug therapy

23 February 2009

By Ben Jones

Appeared in BioNews 496

A phase 2 trial for a radical new, 'one shot' treatment for HIV (human immunodeficiency virus) has shown small but promising results. The research at the University of California, Los Angeles (UCLA), was published in the journal Nature Medicine and was described by the study leader Professor Mitsuyasu as a 'proof of concept' and a reason to continue research in this area.

The technique involved the extraction of white blood stem cells from the patients participating in the study, infecting these cells with a genetically engineered mouse virus called OZ1, which alters the genetic information of the cells in a manner that targets and inactivates HIV genes. These HIV immune cells are then cultured and transfused back into the patients, where they are intended to propagate the immune system with HIV resistant cells as the old infected cells die off.

The study found that after 48 weeks there was no difference between the OZ1 and the placebo groups. However after 100 weeks, even though there was still no statistical difference in viral load, there was a small but significant increase in CD4 cells (the critical immune cells killed by HIV and a standard measure for the severity of a patient's HIV infection.) The study also found that when the patients stopped taking the anti-HIV drugs during one stage of the study, those who had received the dose of gene therapy were able to postpone the reinstatement of their treatment for longer than those who had received the placebo.

Though exciting, Keith Alcorn of the HIV information service NAM, noted that 'the viral load responses in this study were very modest, and for any other sort of product would not justify going forward'. HIV is, however, a highly adaptive virus that is quickly becoming resistant to existing treatments. These retroviral drug treatments, though greatly improving the prognosis for people infected with HIV, are also highly demanding of the patient. Daily dosing, with good time keeping and a stable base of nutrition are required to maintain the effectiveness of the treatment and lapses causes irreparable degradation to health. The possibility of a single shot, once off treatment is, in addition to the need for novel therapies to beat resistance, a major driver behind this research.

It is hope that this new gene therapy may enable a clinical equivalent to the curing of a German patient who needed a bone marrow transplant for leukaemia and received one from an individual with HIV resistance. The 'one shot' treatment might enable not just a much easier means of managing HIV but, potentially, might even become a cure.

 

SOURCES & REFERENCES
Medical News Today | 16 February 2009
 
New Scientist | 18 February 2009
 
BBC News Online | 16 February 2009
 
WebMD | 16 February 2009
 
Nature Medicine | 15 February 2009
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

28 January 2013 - by Matthew Thomas 
Altering the genetic makeup of immune cells could provide them with resistance to HIV... [Read More]
05 December 2011 - by Tamara Hirsch 
US scientists have induced long-lasting HIV protection in mice from a single injection. Their study, published in the journal Nature, uses gene therapy to stimulate production of antibodies against the virus... [Read More]
21 June 2010 - by Dr Lux Fatimathas 
A human RNA-based gene therapy trial to combat HIV has passed the first safety test. US researchers modified human blood stem cells to make them resistant to the virus.... [Read More]

16 February 2009 - by Alison Cranage 
A case report published in the New England Journal of Medicine last week details a man who was HIV+ and, following a bone marrow transplant, now has no detectable signs of the virus. Human Immunodeficiency Virus (HIV) enters and destroys cells of the immune system, eventually causing... [Read More]
21 July 2008 - by Evelyn Harvey 
A form of a gene that protects many Africans from certain forms of malaria increases HIV infection risk, according to a new study published in the journal Cell Host and Microbe. Researchers Professor Sunil K Ahuja, from The University of Texas Health Science Center at San Antonio... [Read More]
10 July 2006 - by Heidi Nicholl 
Human T-cells, a vital component of the immune system, have been successfully differentiated from embryonic stem cells (ES cells) for the first time. The work shows that it may be possible in the future to utilise ES cells to help fight diseases affecting the immune system such as... [Read More]
10 January 2005 - by BioNews 
US scientists have identified a genetic variation that partly explains people's different susceptibility to HIV, the virus that causes AIDS. The findings could help doctors tailor treatment to their patients' genetic make-up, say the team, who published their results in the early online edition of the journal Science. Scientists have... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to Login or Register to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
RISK ASSESSMENT:
BREAST CANCER, PREDICTION AND SCREENING
FREE public event in central London, 6.30pm on Thursday 8 May 2014 - find out more HERE

DataLabel Supplying Printed Labels To The UK For Over 15 Years

ANNIVERSARY APPEAL
Please donate HERE, so that the Progress Educational Trust can continue throughout 2014 (and beyond) while keeping BioNews FREE for you to read

The Progress Educational Trust was shortlisted for the Charity Times Awards 2011

Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation